Deciphera, Allakos and Uniqure are all set for important data disclosures.
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.